Overview

Investigating the Effects of QVM149 on MRI Ventilation Defects

Status:
Not yet recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare treatment with QVM149, an inhaler that contains three types of asthma medications compared to an inhaler that contains two types of asthma medications. Both inhalers contain an inhaled corticosteroid, which reduces inflammation in the lungs, and a medication that helps to open up the airways. The investigational inhaler, QVM149, contains a third medication that also works to open up the airways. The investigators will measure the difference in these two treatments with magnetic resonance imaging (MRI) using a special technique using xenon gas to show how gas spreads in the lungs. In healthy lungs, the gas fills the lungs evenly, but in unhealthy lungs, the gas may fill the lungs unevenly and they will appear patchy. The patchy areas are called ventilation defects. A CT of the chest will be done to assess the structure of the lungs. The investigators will also use lung function testing and questionnaires to evaluate the differences between these therapies.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Grace Parraga
Collaborators:
Novartis
Novartis Pharmaceuticals
Treatments:
Bromides
Glycopyrrolate
Mometasone Furoate